Many drugs have been investigated as potentially protective of renal function after cardiac surgery. However, their comparative effectiveness has not been established. We performed an arm-based hierarchical Bayesian network metaanalysis including 95 randomised controlled trials with 28,833 participants, which allowed us to compare some agents not previously compared directly. Renal outcomes, including: the incidence of postoperative renal dysfunction and haemodialysis; serum creatinine level at 24 hours postoperatively; all-cause mortality; and length of hospital and ICU stay, were compared. Exploratory meta-regression was conducted for potential effect modifiers. A random effects model was selected according to the evaluation of model fit by deviance information criteria. Atrial natriuretic peptide (odds ratio (95%CrI) 0.28 (0.17-0.48); moderate-quality evidence), B-type natriuretic peptide, dexmedetomidine, levosimendan and N-acetyl cysteine significantly decreased the rate of postoperative renal dysfunction compared with placebo. Atrial natriuretic peptide (OR (95%CrI) 0.24 (0.10-0.58); low-quality evidence), B-type natriuretic peptide, and dexamethasone significantly decreased the need for haemodialysis. Levosimendan significantly decreased mortality, OR (95% CrI) 0.49 (0.27-0.91); low-quality evidence). The benefit of atrial natriuretic peptide was still apparent when baseline renal function was normal. None of the potential effect modifiers were significantly correlated with our renal outcomes. Atrial natriuretic peptide was ranked best regarding renal dysfunction, haemodialysis and length of hospital stay. Levosimendan was ranked best regarding mortality and ICU stay. However, our results should be interpreted cautiously given the assumptions made about transitivity and consistency.
Introduction
More than one million cardiac surgical operations are performed every year in the United States and Europe [1] . One of the most common and serious complications of such surgery is acute kidney injury, which is associated with markedly increased mortality and morbidity [2] [3] [4] . Its incidence has been reported as up to 55%; acute kidney injury is also associated with development of chronic kidney disease [5, 6] .
The aetiology of acute kidney injury after cardiac surgery is known to be multifactorial and includes inflammatory response, oxidative stress, transient haemodynamic derangement and ischaemia-reperfusion injury [7] [8] [9] . Many pharmacological agents targeting the different causes have been tested for their ability to protect renal function after cardiovascular surgery [10, 11] . However, previous randomised controlled trials (RCT) of these drugs were mostly small and had limitations. Although many previous meta-analyses pooled the results of previous RCTs comparing one of these agents with placebo control [11] , a head-to-head comparison of pharmacological interventions has rarely been performed so far since no single agent has been definitely and consistently shown to possess clinical efficacy. Therefore, although many drugs with various mechanisms of action have been studied, little is known about their comparative effectiveness. Such a comparison is required to review the current status of evidence and to guide further clinical trials.
Network meta-analysis is a statistical technique that enables comparison of different interventions or drugs that have not been directly compared through adequately powered head-to-head RCTs [12] [13] [14] [15] . Even without previous evidence, a comparison between two drugs is possible through a third common comparator [12, 16] , with direct and indirect comparisons integrated to assess multiple interventions at the same time. In addition, it is possible to determine which modalities are superior according to statistical inference, and estimate the relative ranking.
Therefore, the primary aim of this review was to compare the efficacy of pharmacological agents for protecting renal function during cardiac surgery. For this purpose, we performed a comprehensive network meta-analysis of RCTs comparing renoprotective drugs in the setting of cardiac surgery.
Methods
This study was performed according to the recommendations from the Cochrane Handbook for Systemic Reviews of Interventions [17, 18] and is reported according to the PRISMA extension statement for network meta-analysis [19] .
We aimed to include RCTs evaluating the renoprotective effects of any of the following thirteen drugs used pre-operatively and/or intra-operatively: atrial natriuretic peptide; B-type natriuretic peptide; dopamine; fenoldopam; statin; sodium bicarbonate; levosimendan; methylprednisolone; N-acetyl cysteine; dexamethasone; dexmedetomidine; albumin; and erythropoietin. Drugs were included in our analysis if there were at least two RCTs comparing the drug with a placebo control and reporting at least one of the three renal outcomes of our interest. Our three renal outcomes were: the incidence of postoperative acute kidney injury, acute renal failure or renal dysfunction; the incidence of postoperative haemodialysis; and 24-h serum creatinine.
Eligible participants were those who underwent cardiac surgery, including coronary artery bypass surgery and/or valve replacement surgery and/or thoracic aortic surgery, and/or any adult open heart surgery with or without cardiopulmonary bypass. Quasi-randomised and cluster-randomised trials were not included. Studies that enrolled patients who developed acute kidney injury after surgery were excluded.
Two authors (MH, WK) independently searched MEDLINE via the PubMed interface, Embase databases and the Cochrane Central Register of Controlled Trials (central, issue 11 of 2016) from inception to November 2016. The same authors independently reviewed the titles and abstracts of all searched studies to identify eligible trials. The search strategy for PubMed, Embase, and Cochrane central registry is shown in the Supporting Information. An additional search was performed by a examining the references of the trials included in our meta-analysis or previous meta-analyses of the thirteen drugs. The last search update was in December 2016.
Data were independently extracted from the included studies by two authors (MH, WK) using a uniform data extraction form developed by the authors. Any discrepancies were resolved through consensus discussion. We contacted authors of primary publications for unclear information or missing outcome data or further details of the trial results. The following information was extracted from each trial: the first author of the trial; location of the study; year of publication; the number of enrolled patients; the definition of renal dysfunction and the distribution of outcome data.
The pre-specified primary end-point was the incidence of postoperative renal dysfunction or acute kidney injury defined by criteria devised by the authors or any of the following three sets of diagnostic criteria: RIFLE (risk, injury, failure, loss of function and endstage renal disease); AKIN (Acute Kidney Injury Network); and KDIGO (kidney disease improving global outcomes) criteria [20] . Secondary outcomes were: the incidence of postoperative new-onset dialysis; serum creatinine at 24 h after surgery; postoperative all-cause mortality; and length of hospital or ICU stay. When a median with its interquartile range was reported, the median value was regarded as the mean and the standard deviation was imputed according to the estimate that the interquartile range is approximately 1.35 standard deviations [17] .
To address the heterogeneity of inclusion criteria, a sub-group analysis of patients with normal preoperative renal function was performed, in which only studies that enrolled patients with normal pre-operative renal function were included. Sub-group analysis of patients with pre-existing renal dysfunction could not be performed due to a small number of studies.
The risk of bias of individual studies was assessed using the bias domains described in the Cochrane Handbook for Systemic Reviews of Interventions, version 5.1.0 [17, 21] . The grades of recommendation, assessment, development and evaluation (GRADE) approach was used to rate the quality of evidence [22] [23] [24] . In this approach, the rating of direct evidence from RCTs starts at a high quality and can be rated down based on the risk of bias, indirectness, imprecision, inconsistency, and/or publication bias to levels of moderate, low and very low quality. Secondly, the rating of indirect estimates starts at the lowest rating of the two pairwise estimates that contribute as first-order loops to the indirect estimate but can be rated down further for imprecision or intransitivity. Thirdly, if direct and indirect estimates were similar, the higher rating can be assigned to the network meta-analysis estimates. A 'comparison-adjusted' funnel plot was used to evaluate the presence of small-study effects in the network meta-analysis [25] .
Data were analysed using R version 3.4. [26] . Along with analysis of the direct within-trial comparisons between two pharmacological agents, the mixed technique comparison framework enabled incorporation of an indirect comparison of different agents. Model fit was measured by assessment of the posterior residual deviance and goodness of model fit was evaluated by comparing Dbar, leverage and deviance information criterion between random effects and fixed effect models [27] . We selected a random effects Bayesian model according to the residual variance as well as the deviance information criterion (see also Supporting Information, Table S1 ).
Pairwise associations between each modality were depicted by a graphical representation of the network. Network estimates from all outcome variables were presented as odds ratios or SMD with 95% credible intervals (CrIs). Transitivity and consistency are the important assumptions of network meta-analysis related to the validity of indirect and mixed estimates [28] . The plausibility of transitivity assumption was evaluated based on the individual study characteristics. We assessed potentially important effect-modifying covariates including: patient age; proportion of male sex; hypertension; diabetes mellitus; baseline cardiac systolic function; baseline renal function measured by serum creatinine and glomerular filtration rate; and duration of cardiopulmonary bypass. We conducted an exploratory meta-regression, and regression coefficients of the effect modifying covariates were calculated [29] .
The loop-specific consistency of the direct and indirect evidence could not be assessed formally because there was no closed triangle or quadratic loop in our network. To rank the treatments for an outcome, the comparative influence of all pharmacological interventions to protect renal function with the unique dimension was estimated from multidimensional scaling approach [30] . Relative ranking plots were drawn with this unique dimension. Cumulative ranking plots were drawn based on the clustered analysis of the surface under the cumulative ranking (SUCRA) probabilities calculated by both the model without adjustment and model adjusted for small-study effects. The SUCRA value is the percentage of efficacy or safety achieved by an agent compared with an imaginary agent that is always the best without uncertainty. For example, a SUCRA of 80 means that the intervention in question offers 80% of the effectiveness of an imaginary best intervention. Finally, clustered ranking plots of the network were depicted based on the clustered analysis of the SUCRA probabilities for two different outcomes [30] . We used the SUCRA values adjusted for small-study effects in the clustered ranking plot. Figure 1 shows the search results and reasons for exclusion from the review. See the Supplementary Information for details of the 95 included RCTs and reasons for exclusion after full text review of 98 studies. Table 1 summarises the studies and outcomes. Five studies were published before the year 2000 and the remaining 90 studies were published between 2000 and 2016. Our sub-group analysis of normal preoperative renal function included 5022 patients from 36 trials. Table 2 and Table S3 show the number of included studies and enrolled patients according to the individual drugs. Figure 2 and Figure S1 show the geometry of the network for the incidence of renal dysfunction and other outcomes. Figure 3 shows network estimates of each drug compared with placebo according to the important three outcomes. Table S4, Table S5 and S15 show all network estimates of all possible pairs of drug comparison. Atrial natriuretic peptide, B-type natriuretic peptide, dexmedetomidine, levosimendan, and N-acetyl cysteine significantly decreased the incidence of postoperative acute kidney injury compared with placebo. Moreover, atrial natriuretic peptide and B-type natriuretic peptide significantly decreased the incidence of postoperative dialysis compared with placebo. For atrial natriuretic peptide, the results were: acute kidney injury, odds ratio [OR] (95%CrI) 0.28 (0.17-0.48), SUCRA = 90.2, moderate quality of evidence; and dialysis, OR (95%CrI) 0.24 (0.10-0.58), SUCRA = 87.2, low quality of evidence (Table S15) . Twenty-four hour serum creatinine values for atrial natriuretic peptide and fenoldopam were significantly lower than those for placebo (see also Supporting Information, Table S4 ). Among the drug-to-drug comparisons, atrial natriuretic peptide decreased the incidence of acute kidney injury compared with statins, dexamethasone, erythropoietin, methylprednisolone and N-acetyl cysteine. Atrial natriuretic peptide also significantly decreased the incidence of dialysis compared with erythropoietin and N-acetyl cysteine.
Results
Levosimendan significantly decreased all-cause mortality compared with placebo, OR (95%CrI) 0.49 (0.27-0.91), SUCRA = 79.4, moderate quality of evidence. Atrial natriuretic peptide and levosimendan significantly decreased hospital stay, SMD (95%CrI) for atrial natriuretic peptide À3.55 (À5.38 to À1.73), SUCRA = 71.8, moderate quality of evidence; and levosimendan, fenoldopam, erythropoietin and atrial natriuretic peptide significantly decreased ICU stay, SMD (95%CrI) for levosimendan À1.65 (À2.63 to À0.67), SUCRA = 94.8, low quality of evidence (see also Supporting information, Table S5 ). Levosimendan significantly decreased ICU stay compared with statin, albumin, dexamethasone and dexmedetomidine. Figure S2 shows the network of drug comparisons for the sub-group analysis of the patients with normal pre-operative renal function. Tables S6, S7, and S8 show the network pooled estimates of this sub-group analysis. Atrial natriuretic peptide (OR (95%CrI) 0.24 (0.14-0.41)) and erythropoietin significantly decreased the risk of acute kidney injury. Atrial natriuretic peptide significantly decreased the risk of haemodialysis compared with placebo, OR (95%CrI) 0.25 (0.09-0.69). Twenty-four hour creatinine was significantly lower with atrial natriuretic peptide compared with placebo, SMD (95%CrI) À0.17 (À0.29 to À0.04). No drug significantly decreased all-cause mortality compared with placebo. Atrial natriuretic peptide, erythropoietin and levosimendan significantly decreased length of hospital stay and erythropoietin and levosimendan significantly decreased length of ICU stay.
The plausibility of transitivity assumption was evaluated based on the individual study characteristics. The covariate distributions for loop-specific comparisons and direct pairwise comparisons are shown in Table S2 . The assessment of transitivity from the individual study characteristics showed that there was no major threat to the transitivity assumption. None of the regression coefficients (95%CI) of the meta-regression analyses examining possible effect modifiers turned out to be statistically significant regarding the incidence of renal dysfunction, these being: age, We ranked the comparative effectiveness of 13 drugs according to our six outcomes both in all patients and in the sub-group of patients with normal renal function (Fig. 4 , see also Supporting Information, Figs. S3 and S4, Tables S9 and S10). Figure 5 , Figs. S5 and S6 show the cumulative ranking plots of the individual drugs in all patients and sub-group. Atrial natriuretic peptide had the highest likelihood of preserved postoperative renal function, the lowest incidence of dialysis, and shorter hospital stay both in all patients and the sub-group with normal renal function (see also Supporting Information, Table S11 ). Levosimendan had the highest probability of being the best in mortality and ICU stay for both group anaylses. The clustered ranking plot was depicted based on SUCRA values according to the paired comparison of postoperative renal dysfunction and mortality (Fig. 6 ) and length of hospital and ICU stay (Fig. 7) . Atrial natriuretic peptide, B-type natriuretic peptide, dexmedetomidine and levosimendan were ranked highly regarding both renal dysfunction and mortality and levosimendan, fenoldopam, erythropoietin, Atrial natriuretic peptide and B-type natriuretic peptide were ranked highly regarding the length of hospital and ICU stay.
The comparison-adjusted funnel plots for assessing small-study effects within each network of interventions were depicted in Fig. S7 . The funnel plot for haemodialysis was symmetrical, but the plots for the other outcomes showed outliers, suggesting the source of small study effects.
Overall, the quality of evidence from available studies ranged from moderate to very low by outcomes (see also Supporting Information, Table S12 ). Many included studies were at high or unclear risk of bias, while the studies of fenoldopam, methylprednisolone, N-acetyl cysteine, atrial natriuretic peptide and sodium bicarbonate were at low risk of bias (see also Supporting Information, Fig. S8 ). Table S12 summarises the GRADE quality of evidence supporting the use of all pharmacological agents, compared with placebo. In most comparisons, there was a serious imprecision in summary estimate because the 95% confidence interval was wide and crossed unity. Based on the observed incidence of renal dysfunction and overall mortality, we estimated the absolute risk reduction and the number needed to treat. The anticipated absolute effect of reducing the incidence of acute kidney injury and mortality per 1000 patients is presented in Tables S13 and S14. Figure S9 summarises the results of classic pairwise meta-analyses. The data on the actual outcomes of individual studies are also presented for the six outcomes in all studies (Fig. S9) . Atrial natriuretic peptide, B-type natriuretic peptide, dexamethasone, dexmedetomidine, levosimendan and N-acetyl cysteine showed a significant effect on reducing postoperative renal dysfunction.
Discussion
We performed a systematic review and network metaanalysis from 95 RCTs enrolling 28,833 participants and compared thirteen pharmacological agents for preventing renal dysfunction after cardiac surgery. Pooled estimates of atrial natriuretic peptide, B-type natriuretic peptide, and levosimendan showed significant benefits in more than two outcomes. Clustered ranking analysis showed that atrial natriuretic peptide, B-type natriuretic peptide, dexmedetomidine, and levosimendan were ranked higher than other drugs for both renal dysfunction and mortality. Sub-group analysis of those with normal renal function showed that atrial natriuretic peptide and levosimendan were still ranked highly. Atrial natriuretic peptide was ranked the best for preventing renal dysfunction and regarding haemodialysis incidence, 24-h creatinine and length of hospital stay. However, postoperative renal outcomes were reported using various criteria, and inclusion criteria consisted of patients with varied pre-operative renal or cardiac function, causing significant heterogeneity. We addressed the heterogeneity of included studies by conducting an exploratory meta-regression for characteristics potential effect modifiers including: patient characteristics; underlying disease; baseline renal and cardiac function; and cardiopulmonary bypass time. Finally, most of the studies were at unclear or high risk of bias and the quality of evidence from available studies ranged from moderate to very low. Two RCTs included in our study, plus a previous meta-analysis, suggest that atrial natriuretic peptide has a significant renoprotective effect after cardiac surgery [31] [32] [33] . Atrial natriuretic peptide is a polypeptide secreted by the heart in response to atrial distension and has a potent natriuretic and vasodilatory effect. It can suppress an abnormal increase in renin-angiotensin-aldosterone system hormones and catecholamine [34] . Atrial natriuretic peptide showed the highest SUCRA values in postoperative renal dysfunction, mortality and length of hospital stay in our study results and was ranked in the highest position for renal dysfunction, mortality, hospital stay and ICU stay in the clustered ranking plot.
Nesiritide is a recombinant human B-type natriuretic peptide. One trial evaluated the effect of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery and reported its renoprotective effect [35] . However, the result of B-type natriuretic peptide should be interpreted cautiously given that the sample size of B-type natriuretic peptide in our network was relatively small at 421 patients.
Levosimendan is a calcium-sensitising drug with vasodilatory and inotropic properties. The renoprotective effect of levosimendan is thought to be due to its Figure 4 Relative ranking plots of the pharmacological agent network for all patients. Thirteen drugs are ranked according to the incidence of postoperative renal dysfunction.
immunomodulatory, anti-inflammatory, and anti-oxidant properties. Although levosimendan's effect on blood flow to the kidneys during cardiopulmonary bypass is not known, levosimendan significantly improved the ischaemia-reperfusion injury in renal tubules in previous animal studies and therefore has the potential to improve renal function [36] . In our network analysis, levosimendan was ranked highest for reduction in mortality and ICU stay both for all patients and in the sub-group of those with normal renal function, although limited by low quality of evidence. Dexmedetomidine is a central a 2 -agonist that attenuates surgical stress-induced sympathetic responses and results in stable haemodynamics that may contribute to the better preservation of perioperative renal function [37] . It acts on central a 2 receptors in renal peritubular vasculatures and tubules, inducing vascular relaxation and diuresis by inhibiting the release of renin and arginine vasopressin [38, 39] . Dexmedetomidine can protect multiple organs, including the kidney, by attenuating ischaemia/reperfusion injury and the inflammatory response [34] .
There have been several meta-analyses comparing single pharmacological agents with placebo on clinical outcomes, with significant results [33, 40, 41] . However, there are few meta-analyses comparing multiple drugs. A Cochrane review from 2013 of 72 studies investigated whether any single specific drug can protect renal function in any type of surgery [42] . However, the authors found no reliable evidence that interventions during surgery can protect the kidney. There was significant heterogeneity in defining renal dysfunction, and most of the included studies had poor methodological quality. Another meta-analysis and an overview of seven systematic reviews reported that natriuretic peptides reduced the incidence of haemodialysis after cardiac surgery without any benefit on mortality; this is consistent with our results [11, 43] .
The fundamental question to ask before performing a network meta-analysis should be whether the included studies are sufficiently homogeneous to be quantitatively integrated [44] . The distribution of effect modifiers should be similar across the studies to ensure the validity of a network meta-analysis [28, 29] . To adjust for the effect modifiers, we conducted exploratory meta-regression analyses for the potential variables. None of the regression coefficients of the meta-regression examining possible effect modifiers turned out to be statistically significant.
Renal outcomes after cardiac surgery were our primary end-point. However, we found significant heterogeneity in the criteria for diagnosing postoperative renal dysfunction [20] . Among the 58 studies reporting renal outcomes, 16 studies used AKIN criteria, 10 studies used RIFLE criteria, and four used KDIGO criteria. The remaining 28 studies used the authors' own definition using rises in the serum creatinine level. Therefore, it was not possible to construct a network of thirteen drugs with RCTs comparing renal outcomes using a single, uniform criterion. Given the lack of a standard definition of renal dysfunction, the results of our network meta-analysis should be applied only cautiously to clinical practice. As alternatives for measuring renal dysfunction, the incidence of haemodialysis and 24-h serum creatinine levels were compared, but these variables were reported in fewer than half of the included studies, and the absolute value of creatinine, is in any case, a non-specific measurement. Postoperative urine output was also considered as an outcome variable, but the time of reporting and unit of measurement varied among studies.
Our analysis has several important limitations. Firstly, our network mostly comprised RCTs comparing a drug with placebo. Therefore, most of the network estimates between the drugs came from indirect estimates and the loop-specific consistency could not be evaluated. Secondly, for outcomes such as haemodialysis and mortality, some studies had low or no event rates in one or both trial arms. Consequently, the credible intervals (CrIs) for some drugs for those outcomes were very wide, resulting in increased uncertainty. Thirdly, the definitions of the outcome variables differed markedly between studies and, in particular, for the renal outcomes as mentioned above [20] . Authors' own definitions usually used the degree of creatinine elevation and/or requirement for haemodialysis, consistent with Figure 6 The clustered ranking plot of the 13 renoprotective drugs based on clustered analysis of SUCRA (surface under the cumulative ranking plot analysis) values for the paired outcomes incidence of renal dysfunction and overall postoperative mortality. Each dot is located according to the two SUCRA values of each drug for the two outcomes on the x and y axes, respectively. A larger SUCRA value denotes a higher better rank for the drug. The drug located in the right upper corner has higher SUCRA values for both variables and is regarded as the better of the two drugs compared. ANP, atrial natriuretic peptide, BNP, B-type natriuretic peptide. RIFLE, AKIN, and KDIGO criteria. Nonetheless, pooling data with similar but different various renal endpoint criteria might possibly have introduced bias that influenced our result. Fourthly, the inclusion criteria varied across the trials, which variously included patients with normal pre-operative renal function, preexisting renal dysfunction or a mixture of both. To address this heterogeneity, sub-group analysis was performed for the patients with normal pre-operative renal function. Fifthly, our included studies were published over a long period of time (between 1989 and 2016), 44% being published before 2010. Different clinical practice over this long period of time may affect the outcome variables but also the applicability of our findings to current patient care. Consequently, whether our findings translate into clinically relevant differences still remains to be determined in future well-designed randomised trials. We also advocate standardisation of renal outcome definitions in further studies in order to establish more reliable evidence.
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